" class="no-js "lang="en-US"> Ginkgo Bioworks - Medtech Alert
Tuesday, April 16, 2024
Ginkgo Bioworks | Pharmtech Focus

Ginkgo Bioworks

About Ginkgo Bioworks

Ginkgo Bioworks

Headquartered in Boston, Ginkgo Bioworks uses the most advanced technology on the planet—biology—to grow better products. The company’s cell programming platform is enabling the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. Ginkgo is also actively supporting a number of COVID-19 response efforts, including community testing, epidemiological tracing, vaccine development and therapeutics discovery.

Related Story

Ginkgo Bioworks and WARF Announce Partnership to Discover Next Generation GD2 CAR T-Cell Therapies

April 13 2023

The Wisconsin Alumni Research Foundation (WARF), which has a mission of supporting research at the University […]

Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology

January 9 2023

Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and Ginkgo Bioworks, which […]

Ginkgo Bioworks and the Rwanda Development Board Announce Plans to Develop and Implement New Biosecurity Capabilities in Rwanda

August 12 2022

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and the Rwanda Development […]

Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

August 12 2022

Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases […]

Ginkgo Bioworks Appoints Kathy Hopinkah Hannan to its Board of Directors

August 5 2022

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Kathy […]

Ginkgo to Acquire Zymergen

July 26 2022

Today, Ginkgo Bioworks (NYSE: DNA) — the leading horizontal platform for cell programming — and […]

Concentric by Ginkgo Crosses 10 Million Samples Tested and Expands Testing and Sequencing Capabilities to Detect Monkeypox and Other Pathogens, as Part of Scaling Its Global Biosecurity Infrastructure

June 27 2022

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced plans to further […]

Ginkgo Bioworks and Novo Nordisk to Collaborate on Expression Systems for Pharmaceutical Products

June 8 2022

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo […]

Ginkgo Bioworks Acquires Bitome, an Integrated Metabolite Monitoring Platform

June 7 2022

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that it has […]

Ginkgo Bioworks and First Serv Announce Plans to Develop and Implement Innovative Global Biosecurity Capabilities in Qatar

May 19 2022

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, and First Serv, a […]

Twist Bioscience and Ginkgo Bioworks Sign New Collaboration

April 7 2022

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality […]

Microba Life Sciences and Ginkgo Bioworks Announce Partnership to Discover Novel Live Biotherapeutics

April 5 2022

Microba Life Sciences (ASX:MAP), a precision microbiome science company, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform […]

Antheia and Ginkgo Bioworks Announce Partnership to Accelerate Production of Essential Medicines Using Synthetic Biology

August 13 2021

Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, and Ginkgo Bioworks, which is building the […]

Aldevron's Collaboration with Ginkgo Bioworks Yields Manufacturing Breakthrough for Vaccinia Capping Enzyme Used for Manufacturing of mRNA Vaccines

August 11 2021

Aldevron, a leading research to GMP biomanufacturer of plasmid DNA, mRNA, and proteins, and Ginkgo Bioworks, […]